Results 151 to 160 of about 6,610 (202)

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
Aernout D. van Haarst, Sabina Paglialunga, Ziv Machnes, Ikuo Yamamiya, Nanae Hangai, Aram Oganesian   +5 more
wiley   +1 more source

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1

Leukemia
Khalid Shoumariyeh, Stefan Haug, Juliana Schwaab, Julie K. Pfeil, Jannis Stappenbeck, Annette Schmitt-Graeff, Nicole Naumann, Greta Waltemode, Robert Zeiser, Cornelius Miething, Wolf-Karsten Hofmann, Manja Meggendorfer, Sven Diederichs, Justus Duyster, Andreas Reiter   +14 more
openaire   +2 more sources

S1‐Leitlinie Schweißdrüsenkarzinom

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 9, Page 1356-1384, September 2026.
Zusammenfassung Die aktuelle Einteilung der Schweißdrüsenkarzinome erfolgt nach histomorphologischen Charakteristika und unterscheidet mehr als 20 Entitäten. Es sind meist Patienten höheren, bei einigen Subtypen aber auch mittleren und jüngeren, Lebensalters betroffen. Die Mehrheit der Tumoren entsteht de novo.
Mirjana Ziemer, Michael Erdmann, Abbas Agaimy, Jürgen C. Becker, Almut Böer‐Auer, Doris Helbig, Cornelia Erfurt‐Berge, Alexander Frisman, Conrad Hempel, Ulrike Leiter, Friedegund Meier, Thomas Mentzel, Lara Racz, Silke Redler, Stefan Schliep, Clemens Seidel, Alpaslan Tasdogan, Jochen Utikal, Carsten Weishaupt, Selma Ugurel   +19 more
wiley   +1 more source

FGFR1 Rearrangement Analysis [PDF]

, 2020
openaire   +1 more source

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma

Therapy resistance is a major limitation in therapeutic efficacy for glioblastoma (GBM) patients, positioning GBM among the deadliest tumor types. In this work, we have dissected resistance mechanisms in GBM, which resulted in the identification of FGFR1
Durán, Raúl V, Oltra, Sara S, Tomé, Mercedes, Murdoch, Piedad Del Socorro, Martín-Montalvo, Jorge, Rattigan, Kevin M, Reina-Bando, Ana, Zarzuela, Laura, Morillo-Huesca, Macarena, Ceballos-Chávez, María, Reyes, José C, Helgason, G Vignir, Sierra-Párraga, Jesús M, Moreno-Bueno, Gema, Sánchez-Escabias, Elena, Capilla-González, Vivian, López-Cepero, Ignacio G   +16 more
core   +1 more source

S1 guideline sweat gland carcinoma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 9, Page e1356-e1385, September 2026.
Summary The current classification of sweat gland carcinomas is based on histomorphological characteristics and distinguishes between more than 20 entities. Most patients are older, but some subtypes also affect middle‐aged and younger patients. The majority of tumors arise de novo. Sweat gland carcinomas have nonspecific clinical features.
Mirjana Ziemer, Michael Erdmann, Abbas Agaimy, Jürgen C. Becker, Almut Böer‐Auer, Doris Helbig, Cornelia Erfurt‐Berge, Alexander Frisman, Conrad Hempel, Ulrike Leiter, Friedegund Meier, Thomas Mentzel, Lara Racz, Silke Redler, Stefan Schliep, Clemens Seidel, Alpaslan Tasdogan, Jochen Utikal, Carsten Weishaupt, Selma Ugurel   +19 more
wiley   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

FGFR1 wt Allele [PDF]

, 2020
openaire   +1 more source

Search for FGFR1 inhibitors among chromone derivatives

, 2009
Протеїнкіназа FGFR1 відіграє одну з ключових ролей у регуляції ангіогенезу і проліферації тканин. Інгібітори цієї кінази можна використовувати для ефективного лікування солідних пухлин і ряду проліферативних захворювань.
Грищенко, А.А., Кухаренко, О.П., Ярмолюк, С.М., Бджола, В.Г.   +3 more
core  

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source